Skip to content

    Sharda Cropchem Limited

    SHARDACROP
    Chemicals·31 Oct 2025
    Management Summary

    Sharda Cropchem reported a strong Q2 FY26 with 20% revenue growth to INR929 crores, supported by a 35% volume increase and 690 bps gross margin expansion. EBITDA surged 71% to INR139 crores, reaching a 15% margin. The company maintained a debt-free status and improved working capital, while also planning INR450-500 crores in capex for FY26 to boost product registrations. However, the non-agrochemical segment saw an 11% decline, and management's responses to questions on pricing and agrochemical EBIT variations were notably evasive.

    Highlights

    5
    • Total revenues grew by 20% to INR929 crores in Q2 FY26, driven by global revival in demand and recovery in prices.

    • Overall volume growth stood at 35% in Q2 FY26, with agrochemical segment volume growing by 36% and non-agrochemical by 11%.

    • Gross margins expanded significantly by 690 basis points to 34.5% in Q2 FY26 due to stabilizing input costs.

    • EBITDA increased by 71% to INR139 crores in Q2 FY26, achieving an EBITDA margin of 15%.

    • Working capital days improved by 34 days, standing at 84 days as on September 30, 2025, and the company remains debt-free with INR794 crores in cash and liquid investments.

    Concerns

    3
    • Non-agrochemical business degrew by 11% year-on-year to INR126 crores in Q2 FY26.

    • A minor forex loss was reported in Q2 FY26, although management stated it was notional and related to cross-currency exchange rates.

    • Management was evasive on analyst questions regarding pricing degrowth despite volume growth and significant EBIT variation between Q1 and Q2 for the agrochemical segment.

    What Changed1

    vs Q3 FY26

    Guidance items8 → 5 (-3)
    Key financials

    Metrics

    12

    Periods

    3

    Headline

    3
    • Working Capital Days
      84 days
    • ROCE
      21.6%
    • ROE
      17.5%

    Q2 FY26

    5
    • Revenue
      ₹929 Cr
      YoY+20%
    • Gross Margin
      34.5%
    • EBITDA
      ₹139 Cr
      YoY+71%
    • EBITDA Margin
      15%
    • PAT
      ₹74 Cr
      YoY+75%

    H1 FY26

    4
    • Revenue
      ₹1,914 Cr
      YoY+23%
    • Gross Margin
      35%
    • EBITDA
      ₹281 Cr
      YoY+69%
    • PAT
      ₹217 Cr
      YoY+2.1%

    Segment breakdown

    • Agrochemical (Q2 FY26)₹803 Cr28.2%
    • Non-agrochemical (Q2 FY26)₹126 Cr4.4%
    • Agrochemical (H1 FY26)₹1,649 Cr58.0%
    • Non-agrochemical (H1 FY26)₹265 Cr9.3%
    Donut· Share of Revenue

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    ₹450 crores

    Debt

    Debt disclosed

    Liquidity

    Cash ₹794 crores

    Guidance & targets

    5
    CategoryTargetPriority
    Profitability
    EBITDA Margin
    15% to 18%
    High
    Profitability
    Gross Margins
    similar range to 34.5%
    High
    Revenue
    Revenue Growth
    15%
    Medium
    Revenue
    Full Year Revenue
    INR5,200 crores
    Medium
    Tax
    Effective Tax Rate (Consolidated)
    18% to 20%
    High

    EBITDA margin for H2 FY26

    H2 FY26
    Current15% (Q2 FY26)
    TargetCloser to 19-20% to achieve FY26 guidance of 15-18%

    Why it matters

    Management indicated that H2 margins would need to be significantly higher to meet the full-year guidance, making this a key performance indicator.

    We do expect that. But what I'm saying -- telling is 15% to 18% for the full year, which will be if it goes up from 15% to 17%, then it has to be contributed by a higher margin in the second half, which would be more than 18% to 19%.

    How to verify

    key_financials.metrics[label='EBITDA Margin (H2 FY26)']

    Risks & concerns

    4
    RiskSeverity

    Forex fluctuations leading to losses

    Analyst noted a forex loss in Q2 despite stable euro-dollar rates, but management clarified it was a notional, unrealized loss primarily due to capex payable realignment and cross-currency exchange rates, not a real operational loss.Analyst downplayed

    low

    Pricing degrowth in agrochemical segment

    Analyst observed that agrochemical revenue growth (27%) was lower than volume growth (36%), implying negative realization. Management stated the pricing degrowth was 'very minimum' but did not elaborate further.Analyst downplayed

    medium

    Significant EBIT variation in agrochemical segment

    Analysts repeatedly questioned the substantial drop in agrochemical EBIT in Q2 compared to Q1 despite similar sales, which management was unable to comment on, citing lack of detailed figures.Analyst not addressed

    medium

    Impact of US tariffs on business

    Analyst asked about the impact of US tariffs, and management confirmed there would be no substantial impact, explaining that tariffs are passed on to customers due to the specialized nature of their registered products and limited suppliers.Analyst acknowledged

    low

    Q&A highlights

    7

    “No, sir, because last year same quarter, I think we had a 75% growth in Europe versus North America was negative. So I'm just trying to understand what changed this quarter? R. V. Bubna: Nothing specific that I can comment on.”

    Analyst sought clarity on significant regional shifts in Q2, but management provided no specific explanation for the change in dynamics.

    asked by Ayush Chhabria

    2 min read6 chapters

    Detailed Narrative

    01

    Q2 FY26 Financial Performance Overview

    Sharda Cropchem reported a robust Q2 FY26, with total revenues growing by 20% year-on-year to INR929 crores. This performance was underpinned by a significant overall volume growth of 35%. The agrochemical segment, which is the core business, saw a 27% year-on-year revenue increase to INR803 crores, while its volumes grew by 36%. In contrast, the non-agrochemical segment experienced an 11% year-on-year decline in revenue, reaching INR126 crores.

    02

    Gross Margin Expansion and Profitability

    The company demonstrated strong profitability improvements, with gross margins expanding by 690 basis points to 34.5% in Q2 FY26, compared to 27.6% in Q2 FY25. This expansion was attributed to stabilizing input costs. Consequently, EBITDA for the quarter grew by an impressive 71% year-on-year, reaching INR139 crores, with the EBITDA margin standing at 15%. PAT also saw a substantial increase of 75% year-on-year, amounting to INR74 crores.

    03

    Working Capital and Liquidity Management

    Sharda Cropchem continued its focus on efficient working capital management, with working capital days improving by 34 days to 84 days as of September 30, 2025, compared to March 2025. The company maintains a debt-free status, reinforcing its strong financial position. Furthermore, it held significant cash and liquid investments totaling INR794 crores as of September 30, 2025, providing ample liquidity for future operations and strategic initiatives.

    04

    Product Registrations and Capex Plans

    The company's strategy of securing product registrations globally continues to be a key differentiator. As of September 30, 2025, Sharda Cropchem had 2,994 product registrations, with an additional 1,068 applications in various stages of approval worldwide. To further strengthen its market position and pipeline, the company plans a capital expenditure of INR450 crores to INR500 crores for FY26, with INR250 crores already spent in H1 FY26.

    05

    Regional Performance and Product Mix Dynamics

    Geographically, Europe contributed 43% to the gross margin, NAFTA 23%, LATAM 20%, and the rest of the world 40%. Management clarified that revenue growth is influenced by volume growth (34.8%), FX impact🌐 (1.9%), and product mix (17%). The product mix refers to the varying price points of different products, where higher demand for higher-priced products can lead to increased revenue even with lower volumes, and vice versa, impacting overall margins.

    06

    Forex Impact and US Tariffs Clarification

    Management addressed concerns regarding forex losses, stating that the minor loss reported in Q2 FY26 was notional and primarily due to cross-currency exchange rates and realignment of capex payables. They emphasized that it was not a real operational loss. Regarding US tariffs, the company asserted that there would be no substantial impact on its business, as the specialized nature of its registered products allows for tariffs to be passed on to customers, who are willing to pay due to limited alternative suppliers.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.